Articles: vaccination.
-
Despite high COVID-19 vaccine coverage in Canada, vaccine acceptance and preferred delivery among newcomers, racialized persons, and those who primarily speak minority languages are not well understood. This national study explores COVID-19 vaccine acceptance, access to vaccines, and delivery preferences among ethnoculturally diverse population groups. ⋯ Understanding how newcomers, racialized peoples, and minority language speakers perceive and access COVID-19 vaccines will support vaccination campaigns to optimize equitable access.
-
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is associated with antibodies that target platelet factor 4 (PF4) and are heparin-independent. VITT antibodies are implicated in acute, transient prothrombotic disorders that are triggered by adenoviral vector vaccines against coronavirus disease 2019 or by adenovirus infection. ⋯ The antibody clonotype profiles and binding epitopes on PF4 were different from those observed with the acute disorders occurring after vaccination or viral infection, features that reflect distinct immunopathogenesis. Treatment strategies besides anticoagulation alone are needed for the chronic disorders, referred to as VITT-like monoclonal gammopathy of thrombotic significance. (Funded by the Canadian Institutes of Health Research and others.).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Tenofovir and Hepatitis B Virus Transmission During Pregnancy: A Randomized Clinical Trial.
Standard care for preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV) in highly viremic mothers consists of maternal antiviral prophylaxis beginning at gestational week 28 combined with an HBV vaccine series and HBV immune globulin (HBIG) at birth. However, HBIG is unavailable in some resource-limited areas. ⋯ Among pregnant women with HBV and high levels of viremia, TDF beginning at gestational week 16 combined with HBV vaccination for infants was noninferior to the standard care of TDF beginning at gestational week 28 combined with HBIG and HBV vaccination for infants. These results support beginning TDF at gestational week 16 combined with infant HBV vaccine to prevent MTCT of HBV in geographic areas where HBIG is not available.
-
Preventive medicine · Feb 2025
Chronic conditions, COVID-19 vaccination, and institutional trust among Hispanic/Latinx communities in San Diego, California.
Hispanic/Latinx populations have been disproportionately impacted by the COVID-19 pandemic. These populations are also more likely to have chronic conditions, putting them at higher risk of severe COVID-19 outcomes. Vaccination is important to reduce the risk of severe COVID-19 outcomes, but Hispanic/Latinx populations may be less likely to vaccinate due to institutional trust related to experiences of discrimination in healthcare and community disinvestment. Project 2VIDA! is a randomized clinical trial developed to respond to the need for increased trust and vaccine access among these populations in San Diego, California. Analyzing 2VIDA! data, this article seeks to better understand the relationship between chronic health conditions, institutional trust, and vaccination behaviors among a predominantly Hispanic/Latinx sample in San Diego. ⋯ Our findings suggest that widespread communication on the importance of vaccination for older Hispanic/Latinx populations with chronic conditions may have supported vaccination uptake. Targeted messaging and community-based approaches to build trust, combat misinformation, and increase vaccination uptake among younger individuals and Spanish-speakers are needed.